ClinicaliQ Trial Snapshot
- Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease — Recruiting • Phase III • Cardiology / Cardiovascular • NCT07318610.
- What is being tested: Two novel Factor XI inhibitors (REGN7508 and REGN9933) are being evaluated to reduce adverse vascular events in patients with Peripheral Artery Disease (PAD), a condition characterised by narrowed blood vessels in the limbs.
- Patient eligibility overview: The trial targets adult patients with diagnosed Peripheral Artery Disease who are at risk of vascular complications; specific inclusion/exclusion criteria would determine baseline disease severity and co-morbidity requirements.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures like Lower Extremity Revascularization (LER), a procedure to improve blood flow in the legs and feet. The aim of this study is to see how well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who…
Eligibility Snapshot
- Key Inclusion Criteria: 1. Successful LER distal to the external iliac artery for ischemia due to atherosclerotic disease within 10 days prior to randomization as described in the protocol 2. At least 1 of the following enrichment factors for major thrombotic vascular events: 1. Bypass with prosthetic graft 2. Endovascular treatment with stenting 3. Target lesion length >15 cm 4. History of LER or amputation for PAD prior to qualifying LER 5. Type 2 diabetes mellitus requiring pharmacologic treatment 6. Comorbid symptomatic coronary artery disease as described in the protocol 7. Chronic kidney disease as described in the protocol 8. Age ≥75 years Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.